Molnupiravir: COVID drug linked to mutations that could 'spread the illness', scientists say

Anti-Covid drug may have led to virus mutations: study

Pharmaceutical giant Merck’s antiviral pill molnupiravir was one of the earliest treatments rolled out during the pandemic to prevent Covid becoming more severe in vulnerable people.

Research uncovers a link between antiviral drug for COVID-19 and SARS-CoV-2 mutations

Researchers at the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cape Town and UKHSA have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.

How the use of this anti-COVID drug may have led to mutations in the virus

Molnupiravir was one of the earliest treatments rolled out during the pandemic, and works mainly by creating mutations in the virus with the goal of weakening and killing it.

REVEALED: Popular COVID Drug Manufactured by Merck is Causing "Unintended" Virus Mutations, Potentially Fueling COVID's Spread

An international team of researchers has determined that a popular drug manufactured by Merck to treat COVID-19 is driving what is being described as “unintended” mutations in the virus and potentially fueling the virus’s spread The Express reported Monday that these researchers studied a whopping 15 million COVID-19 sequences to determine how it has mutated over time.

Antiviral Coronavirus medicine could be linked to virus mutations

Experts say that regulators must now be proactive in monitoring the effects of drugs which cause mutations.

Potential link found between Merck antiviral and mutated COVID strains

Molnupiravir, known commercially as Lagevrio, is one of two COVID-19 antivirals authorized for treating coronavirus infections along with Paxlovid from Pfizer.